Clinical Trial

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-30
critical Primary endpoint(s) modified 2026-05-30
notable Trial sites expanded: 0 -> 7 locations 2026-05-30
Trial Details
NCT Number NCT07541287
Lead Sponsor Jade Biosciences, Inc.
Conditions IgA Nephropathy
Enrollment 30 participants
Start Date 2026-05-19
Primary Completion 2029-01 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-07